EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy

Nina Lykkegaard Gehr, Christina Mortensen, Tore B Stage, Malene Roland Vils Pedersen, Søren Rafael Rafaelsen, Jonna Skov Madsen, Dorte Aalund Olsen, Signe Timm, Lars Henrik Jensen, Torben Frøstrup Hansen, Nanna Brix Finnerup, Lise Ventzel

Cancer Chemotherapy and Pharmacology · 2025-12 · 95 (1)

DOI: 10.1007/s00280-025-04773-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 10.04.2025. Verfasst von Nina Lykkegaard Gehr und 11 weiteren Autor:innen. Beteiligte Einrichtung: Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. ninalykgehr@clin.au.dk. Hauptthemen laut MEDLINE: Oxaliplatin, Neurofilament Proteins, Peripheral Nervous System Diseases, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aarhus Universitet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Oxaliplatin-induced peripheral neuropathy (OIPN) is a chronic, debilitating late effect following oxaliplatin treatment. Neurofilament light chain (NfL) is a structural protein found in nerve axons that was investigated upon oxaliplatin exposure in vitro and in vivo correlated to symptoms of OIPN in colorectal cancer patients receiving oxaliplatin.

Methods

Human sensory neurons, derived from induced pluripotent stem cells, were exposed to clinically relevant concentrations of oxaliplatin in vitro, with NfL concentrations measured in the cell medium. The prospective clinical study included patients with colorectal cancer undergoing chemotherapy therapy with or without oxaliplatin. Possible OIPN was defined as bilateral presence of numbness and/or presence of pricking sensations in the feet documented in an interview at the time of blood sampling prior to, 3, and 6 months after initiating treatment.

Results

Oxaliplatin exposure led to a dose-dependent NfL increase in vitro. In the clinical cohort of 30 patients (18 in the oxaliplatin group), NfL levels rose at 3 and 6 months compared to controls. NfL level changes correlated to OIPN symptoms at the 6-month timepoint (rho 0.81, p < 0.001). However, the interindividual variation was substantial, and most patients showed only a minor increase in NfL.

Conclusion

Both in vitro and clinical data indicate that oxaliplatin exposure results in elevated NfL levels. Further prospective studies are needed to evaluate NfL as an early biomarker for OIPN, specifically focusing on the timing of blood sampling during chemotherapy treatment to enable the timely reduction of oxaliplatin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxaliplatinNeurofilament ProteinsPeripheral Nervous System DiseasesAntineoplastic AgentsColorectal NeoplasmsOrganoplatinum CompoundsHumansMaleFemaleMiddle AgedProspective StudiesAgedBiomarkersDose-Response Relationship, DrugAdultInduced Pluripotent Stem Cells

Stichwörter der Autor:innen

BiomarkerChemotherapy-induced peripheral neuropathyColorectal cancerNeurofilament light chainSensory neurons

Substanzen

OxaliplatinNeurofilament ProteinsAntineoplastic Agentsneurofilament protein LBiomarkersOrganoplatinum Compounds

Autor:innen und Institutionen

  • Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. ninalykgehr@clin.au.dk.
  • Department of Oncology, University Hospital of Southern Denmark, Vejle, Denmark. ninalykgehr@clin.au.dk.
  • Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Vejle, Denmark.
  • Department of Radiology, University Hospital of Southern Denmark, Vejle, Denmark.
  • Department of Clinical Biochemistry and Immunology, University Hospital of Southern Denmark, Vejle, Denmark.

Förderung

  • Aarhus Universitet

Zitieren

APA

Gehr, N. L., Mortensen, C., Stage, T. B., Pedersen, M. R. V., Rafaelsen, S. R., Madsen, J. S., Olsen, D. A., Timm, S., Jensen, L. H., Hansen, T. F., Finnerup, N. B., & Ventzel, L. (2025). Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy. Cancer Chemotherapy and Pharmacology, 95(1). https://doi.org/10.1007/s00280-025-04773-w

Vancouver

Gehr NL, Mortensen C, Stage TB, Pedersen MRV, Rafaelsen SR, Madsen JS, et al. Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy. Cancer Chemotherapy and Pharmacology. 2025;95(1). doi:10.1007/s00280-025-04773-w

BibTeX
@article{Gehr2025,
  author = {Gehr, Nina Lykkegaard and Mortensen, Christina and Stage, Tore B and Pedersen, Malene Roland Vils and Rafaelsen, Søren Rafael and Madsen, Jonna Skov and Olsen, Dorte Aalund and Timm, Signe and Jensen, Lars Henrik and Hansen, Torben Frøstrup and Finnerup, Nanna Brix and Ventzel, Lise},
  title = {Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  volume = {95},
  number = {1},
  doi = {10.1007/s00280-025-04773-w}
}
Kostenlos starten →